Hepatitis C inhibitor compounds

US9340539B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Christian Brochu · Blainville, CA
• Chantal Grand-Maitre
• Lee Fader · Laval, CA
• Cyrille Kuhn · Danbury, US
• Megan BERTRAND-LAPERLE · Laval, CA
• Marc Pesant · St. Helena, US

Key dates

• Filing date: Aug 22, 2012
• Grant date: May 17, 2016
• Expiry date: Aug 22, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/107
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: X1 and X2 are each independently CRB or N; RB is H, (C1-6)alkyl, (C1-6)haloalkyl, halo. —O—(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; R1 and R2 are each independently (C1-6)alkyl optionally mono- or di-substituted with —O—(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; or R1 and R2, together with the carbon to which they are attached, are linked to form a (C3-7)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with —(C1-6)alkyl; RA is —C(═O)N(R3)(R4), —C(═O)O(R4), heterocyclyl or heteroaryl, wherein each said heterocyclyl and heteroaryl is optionally substituted 1 to 3 times with R41; R5 and R6 are each independently H or (C1-6)alkyl optionally mono- or di-substituted with —O—(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; or R5 and R6, together with the carbon to which they are attached, are linked to form a (C3-7)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with —(C1-6)alkyl; and n is 0, 1…